Literature DB >> 19596921

Expression of MMP-7, MMP-9, TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease.

J Safranek1, M Pesta, L Holubec, V Kulda, J Dreslerova, J Vrzalova, O Topolcan, M Pesek, J Finek, V Treska.   

Abstract

UNLABELLED: The expression of matrix metallo-proteinases (MMP-7 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2), which are involved in the degradation of the extracellular matrix (ECM) and tumor growth, was investigated in normal lung tissue, tissue of benign pulmonary diseases and non-small cell lung cancer (NSCLC) tissue. PATIENTS AND METHODS: Tumor tissue and surrounding carcinoma-free lung tissue samples were obtained from 91 patients with NSCLC who had undergone surgery in the years 2005-2007 as well as lung tissue from 12 patients operated on for 'benign' bullous emphysema or interstitial lung disease. The mRNA was isolated from the tissues and the expression of mRNA was assessed using a real-time RT PCR method.
RESULTS: Significantly higher expression of MMP-7, MMP-9 and TIMP-1 mRNA was demonstrated in the NSCLC tissue in comparison with the normal lung tissue from the same patients (p=0.0003, p<0.0001 and p=0.0018, respectively). Similar results for MMP-7, MMP-9 and TIMP-1 were found in the histological subgroups: squamous cell lung cancer vs. normal tissue (p=0.0198, p=0.0015 and p=0.0366, respectively), and adenocarcinoma vs. normal tissue (p=0.0045, p<0.0001 and p=0.0140, respectively). The expression of MMP-7 was found to be significantly higher in tumor tissue vs. lung tissue of the benign diseases (p=0.0086) and similar results were also recorded in the histological subgroups: squamous cell lung cancer vs. benign tissue (p=0.0171) and adenocarcinoma vs. benign tissue (p=0.0135). The expression of MMP-9 was significantly higher only in the adenocarcinoma subgroup vs. the benign tissue (p=0.0412). No differences in the expression of mRNA between stage IA and stages IB-IIIB of NSCLC were recorded.
CONCLUSION: Significantly higher expression of MMP-7 and MMP-9 in tumor tissue than in the surrounding tissue or in benign lung disease tissue supports the notion of an important role of these metalloproteinases in the growth of lung carcinoma. TIMP-1 expression is increased only in carcinoma, but not in benign lung disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596921

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  29 in total

1.  Altered gene expression in conjunctival squamous cell carcinoma.

Authors:  Alka Mahale; Hind Alkatan; Saeed Alwadani; Maha Othman; Maria J Suarez; Antoinette Price; Hailah Al-Hussain; Sabah Jastaneiah; Wayne Yu; Azza Maktabi; Edward P Deepak; Charles G Eberhart; Laura Asnaghi
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

2.  Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer.

Authors:  Wei Yu; Li Chen; Yu-Qing Yang; John R Falck; Austin M Guo; Ying Li; Jing Yang
Journal:  Cancer Chemother Pharmacol       Date:  2010-12-01       Impact factor: 3.333

3.  Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential.

Authors:  Jeppe Thorlacius-Ussing; Stephanie Nina Kehlet; Sarah Rank Rønnow; Morten Asser Karsdal; Nicholas Willumsen
Journal:  J Cancer Res Clin Oncol       Date:  2018-11-22       Impact factor: 4.553

4.  Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung.

Authors:  Sonam A Shah; Francis G Spinale; John S Ikonomidis; Robert E Stroud; Eileen I Chang; Carolyn E Reed
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04       Impact factor: 5.209

5.  Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study.

Authors:  D Pastuszak-Lewandoska; J Kordiak; K H Czarnecka; M Migdalska-Sęk; E Nawrot; D Domańska-Senderowska; J M Kiszałkiewicz; A Antczak; P Górski; E Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-07-22       Impact factor: 3.064

Review 6.  Genetic susceptibility to lung cancer--light at the end of the tunnel?

Authors:  Ariela L Marshall; David C Christiani
Journal:  Carcinogenesis       Date:  2013-01-24       Impact factor: 4.944

Review 7.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.

Authors:  Elin Hadler-Olsen; Jan-Olof Winberg; Lars Uhlin-Hansen
Journal:  Tumour Biol       Date:  2013-05-17

8.  Expression of molecular factors correlated with metastasis in small cell lung cancer and their significance.

Authors:  Xiao-Xia Li; Rui-Jian Li; Lu-Jun Zhao; Ning-Bo Liu; Ping Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Protein signature of lung cancer tissues.

Authors:  Michael R Mehan; Deborah Ayers; Derek Thirstrup; Wei Xiong; Rachel M Ostroff; Edward N Brody; Jeffrey J Walker; Larry Gold; Thale C Jarvis; Nebojsa Janjic; Geoffrey S Baird; Sheri K Wilcox
Journal:  PLoS One       Date:  2012-04-11       Impact factor: 3.240

10.  A mathematical model for microRNA in lung cancer.

Authors:  Hye-Won Kang; Melissa Crawford; Muller Fabbri; Gerard Nuovo; Michela Garofalo; S Patrick Nana-Sinkam; Avner Friedman
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.